Five Competitive Forces in the Biotechnology Industry and Its Economics Scenarios Essay

Words: 1812
Pages: 8

Five Competitive Forces in the Biotechnology Industry and Its Economics Scenarios

Table of Contents Industry Analysis 3 About the Biotechnology Industry 3 The future of Biotech companies is bright 4 Porter's Five Forces 4 Threat of New Entrants 4 Power of Suppliers 4 Power of Buyers 5 Competitive Rivalry 5 Forecast Industry 5 Competitors 6 Economic Scenarios 7 Increased Demand for Money 7 Increase of Money Supply 8 Deflation 9 Price for Biotechnology Products 10 When to Build Inventory? 10

Industry Analysis
About the Biotechnology Industry
The biotechnology industry uses advances in genetics research to develop products for human diseases and conditions. Biologic drugs and products are more complex
…show more content…
These drugs are usually innovative molecules for unmet needs; therefore, payers and patients are less sensitive to price.
Threat of New Entrants
The threat of substitutes in the biotechnology field is low, driven by patent protection. Even after the patents expire, only a few companies are capable of copying biologic products. Because these copied drugs will never be equal to the originator molecule, they are called biosimilars. Biosimilars are not identical and are not easy to reproduce and requires from 8 to10 years and $100M–$200M to develop.
Competitive Rivalry
The rivalry within the biotechnology industry is somewhat intense. Many small biotech companies are operating in the world, but only few make a majority of the revenue.
Forecast Industry
The future of biotechnology is bright. Given the nature of the industry’s products, generic competition has been a less pressing issue than for most traditional pharmaceutical companies. Biotech drugs are difficult and expensive to copy, thus limiting the number of entrants to the generic market. Regulatory procedures to approve biosimilars are relatively new, and only a few companies have the ability to execute them (Roche Holding AG, Merck KGaA, Pfizer, Amgen).
Biotech companies have the potential for entering the biosimilars segment, drawing on its wealth of expertise in manufacturing biological drugs because of decades of proven biologics R&D